Psoriasis

If early therapy with DMARDs can slow disease progression and delay expensive biologic treatment, early screening for psoriatic arthritis among patients with psoriasis could save $220 million each year in Canada and improve quality of life, according to data published in Arthritis Care & Research.

The investigational IL-17A and IL-17F inhibitor bimekizumab was superior to adalimumab in achieving a 90% improvement in Psoriasis Area and Severity Index score after 16 weeks, according to a press release from UCB.

Individuals in the U.S. with psoriasis are at an increased risk for developing migraines, according to a cross-sectional study.

In a top Healio Dermatology story, preliminary findings from Emma Guttman-Yassky, MD, PhD, demonstrate a novel use of dupilumab for managing chronic keloids with reductions in skin fibrosis and keloidal scarring, which may suggest a potential underlying Th2 pathogenesis in keloid formation.

Patients with psoriasis or psoriatic arthritis who are newly treated with IL-12/23 blockers demonstrated a reduced risk for serious infection compared with those who received TNF or IL-17 inhibitors, according to data published in Annals of the Rheumatic Diseases.

No significant increased risk was found for suicidal behavior in a retrospective group of patients with psoriasis and potential concomitant psoriatic arthritis compared with control patients, according to findings from a nationwide study in Taiwan published in American Journal of Clinical Dermatology.

A 90% reduction in Psoriasis Area Severity Index and a 90% decrease in body surface area may help pediatric patients with psoriasis reach optimal quality of life, according to findings published in JAMA Dermatology.

Among a large cohort of patients with psoriasis, researchers found around 20% had an immune-mediated inflammatory disease develop before psoriasis onset and 14% had one develop after psoriasis onset, according to a study using data from the Danish National Patient Registry.

Clinical specialty setting and geographic region can affect the diagnosis timing of psoriatic arthritis, disease management and disease burden, according to researchers in a Healio Dermatology story comparing diagnoses within dermatology and rheumatology.

A machine learning program with clinical and coronary CT angiography data identified the top predictors of noncalcified coronary burden in psoriasis, which were markers related to obesity, dyslipidemia and inflammation, according to research in Journal of the American Academy of Dermatology.